Race CEO Dr Daniel Tillett sits down with Juliette Saly at ausbiz for a check-in on the company’s performance in the last quarter, and the outlook for the rest of…

Race CEO Dr Daniel Tillett speaks to Nadine McGrath at Stockhead in detail about drug repurposing and resurrecting abandoned or underutilised drugs. Dr Tillet explains how commercial decisions contribute to…

Race Oncology (ASX:RAC) CEO Dr Daniel Tillett joins Sarah Hughan at the Stockhead’s What The Facts?! video interview series to discuss side effects of traditional chemotherapy and the importance of protecting heart health…

We thank all our shareholders for their strong interest in the Race Oncology Bonus Options and Piggyback Options Offer. We have been receiving many questions in relation to these options,…

Race Oncology appoints Associate Professor Erin Howden to scientific advisory board Howden has researched adverse effects of chemotherapy on cardiovascular fitness of cancer patients Appointment aims to bring Race Oncology’s…